Advice
following a full submission:
darunavir (Prezista®) 400mg is accepted for use within NHS Scotland.
Indication under review: darunavir 800mg once daily co-administered with low dose ritonavir (100mg once daily) for the treatment of HIV-1 infection in antiretroviral therapy experienced adults with no darunavir resistance associated mutations and who have plasma HIV-1 RNA <100,000 copies/mL and CD4+ cell count ≥100 cells/mm3.
Darunavir 800mg/ritonavir 100mg once daily was demonstrated to be non inferior to darunavir 600mg/ritonavir 100mg twice daily, when administered with an optimised background regimen that consisted of at least two nucleoside
Download detailed advice132KB (PDF)
Medicine details
- Medicine name:
- darunavir (Prezista)
- SMC ID:
- 707/11
- Indication:
- For the treatment of HIV-1 infection in antiretroviral therapy (ART) experienced adults
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 August 2011